

A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT07232407

Status	RECRUITING
Phase	Phase 1
Sponsor	Sichuan Baili Pharmaceutical Co., Ltd.
Enrollment	22 participants

Key Eligibility Criteria

Inclusion (14)

- Voluntarily sign the informed consent form and comply with the protocol requirements;
- Gender: no restriction;
- Age: e18 years and d75 years (Phase Ia); e18 years (Phase Ib);
- Expected survival time e3 months;
- Locally advanced or metastatic solid tumors;
- ... and 9 more (see full listing online)

Exclusion (16)

- Use of chemotherapy, biotherapy, or immunotherapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose;
- History of severe heart disease;
- QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block;
- Active autoimmune or inflammatory diseases;
- Diagnosis of other malignancies within 5 years prior to the first dose;
- ... and 11 more (see full listing online)

Locations (1 total)

Sichuan Cancer Hospital, Chengdu, Sichuan, China